Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2024

Agios Pharm Interest Expense To Sales is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability.

Agios Pharm Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2023 was 115.58%, a -99.96% change year over year.
Agios Pharm Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2022 was 267,274.12%, a 2,222,131.45% change year over year.
Agios Pharm Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2021 was 12.03%, a 20.94% change year over year.
Agios Pharm Interest Expense To Sales for the Trailing 12 Months (TTM) ending March 31, 2020 was 9.95%, a -42.99% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends